Hyperbaric Oxygen therapy (HBOT) is of interest to basic biomedical researchers and to practitioners of complementary and alternative medicine (CAM). HBOT is applied to a wide variety of diseases with symptoms caused by a lack of oxygen in the target tissues. It is not accepted as a treatment by the US medical community due to the lack of understanding of the underlying physiology and yet to be carefully evaluated potential dangers. Extensive pre-clinical studies are required to overcome the current bias towards HBOT and to determine its limitations. The central goal of this proposal is to understand the mechanisms of beneficial effects of HBOT and to identify its potential dangers. We recently established the critical role of the hypoxia-driven and A2A and A2B adenosine receptor (A2AR/A2BR)-mediated pathway in inhibition of overactive inflammatory cells and protection of normal tissues in hypoxic inflamed areas. We hypothesize that the elimination of this mechanism by oxygen during HBOT may explain the beneficial effects of HBOT in clearing infections by """"""""de-inhibited"""""""" immunocytes. We are also concerned that the weakening of this protective mechanism by HBOT may lead to an unintended exacerbation of inflammatory tissue damage. We plan to test our hypothesis in studies of HBOT-treated wild type mice and of unique mice with total and tissue-specific deletion of A2AR and/or A2BR genes in different models of lung inflammation.
Our specific aims #1 and 2 are to test whether HBOT exacerbates lung inflammation in studies of inhalative and intravenously induced models of lung injury in mice, while in Aim #3 we will test whether compensatory treatment with A2AR agonist will prevent the inflammatory lung injury exacerbation by HBOT in order to gain potential benefits of HBOT for other indications in CAM and other therapies. ?

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AT002788-02
Application #
7229973
Study Section
Special Emphasis Panel (ZAT1-DB (19))
Program Officer
Pontzer, Carol H
Project Start
2006-05-01
Project End
2008-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
2
Fiscal Year
2007
Total Cost
$190,558
Indirect Cost
Name
Northeastern University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Kjaergaard, Jorgen; Hatfield, Stephen; Jones, Graham et al. (2018) A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression. J Immunol 201:782-791
Hatfield, Stephen M; Kjaergaard, Jorgen; Lukashev, Dmitriy et al. (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7:277ra30
Hatfield, Stephen M; Kjaergaard, Jorgen; Lukashev, Dmitriy et al. (2014) Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1?-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) 92:1283-92
Belikoff, Bryan G; Hatfield, Stephen; Georgiev, Peter et al. (2011) A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol 186:2444-53
Belikoff, Bryan; Hatfield, Stephen; Sitkovsky, Michail et al. (2011) Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock 35:382-7
Sitkovsky, Michail V (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30:102-8
Ohta, Akio; Kjaergaard, J; Sharma, S et al. (2009) In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol 156:297-306
Ohta, Akio; Sitkovsky, Michail (2009) The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol 9:501-6
Ohta, Akio; Ohta, Akiko; Madasu, Manasa et al. (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183:5487-93
Sitkovsky, M; Lukashev, D; Deaglio, S et al. (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153 Suppl 1:S457-64

Showing the most recent 10 out of 12 publications